Critical Covid-19 patient in Hyderabad administered 'experimental' plasma therapy

Published May 3, 2020
The Sindh government had earlier allowed three hospitals in the province to carry out clinical trials for plasma therapy.  — AFP/File
The Sindh government had earlier allowed three hospitals in the province to carry out clinical trials for plasma therapy. — AFP/File

A critical coronavirus patient in Hyderabad has been administered an experimental therapy involving injecting convalescent plasma for passive immunisation to treat the disease, it emerged on Sunday.

The development was confirmed by the Liaquat University Hospital (LUH) isolation ward's focal person Dr Aftab Hussain Phull.

Does plasma therapy treat Covid? Is it safe? Here's all you need to know about the approach

The plasma — donated by a recovered coronavirus patient to the Diagnostic and Research Laboratory at the Liaquat University of Medical and Health Sciences — was administered to a patient under treatment at the isolation ward.

"He was given the plasma after managing his condition as best as possible under the given circumstances," Phull said.

On April 30, the Sindh government had allowed three hospitals in the province to carry out clinical trials for the “experimental use of Covid-19 convalescent plasma for passive immunisation".

The hospitals included the Dr Ruth Pfau Civil Hospital in Karachi, the National Institute of Blood Diseases (NIBD) in Karachi and LUH, a government facility in Hyderabad.

Prior to this, the government had approved clinical trials for plasma therapy in addition to approving locally made ventilators for treating critically ill patients and granting permission for manufacturing sanitisers and producing chloroquine.

What is plasma therapy?

The experimental therapy involves collecting blood from someone who has recovered from Covid-19 and transfusing separated plasma to a critically sick patient; plasma is the clear part of blood that is left when blood cells have been removed and contains antibodies and other proteins.

The transfusion of plasma with its antibodies provides a form of 'passive immunity' to the sick recipient to fight the infection.

The protection offered by passive immunisation, however, is short-lived, usually lasting only a few weeks or months.

The science behind plasma therapy and passive immunisation is not new; the concept has been widely applied for treating different infectious diseases including mumps, measles and polio.

Opinion

Editorial

China security ties
Updated 14 Nov, 2024

China security ties

If China's security concerns aren't addressed satisfactorily, it may affect bilateral ties. CT cooperation should be pursued instead of having foreign forces here.
Steep price
14 Nov, 2024

Steep price

THE Hindu Kush-Himalayan region is in big trouble. A new study unveiled at the ongoing COP29 reveals that if high...
A high-cost plan
14 Nov, 2024

A high-cost plan

THE government has approved an expensive plan for FBR in the hope of tackling its deep-seated inefficiencies. The...
United stance
Updated 13 Nov, 2024

United stance

It would've been better if the OIC-Arab League summit had announced practical measures to punish Israel.
Unscheduled visit
13 Nov, 2024

Unscheduled visit

Unusual IMF visit shows the lender will closely watch implementation of programme goals to prevent it from derailing.
Bara’s businesswomen
13 Nov, 2024

Bara’s businesswomen

Bara’s brave women have proven that with the right support, societal barriers can be overcome.